FOLH1 and prostate cancer: Thereafter, various radioligand-based therapies including radio-attached monoclonal antibody, small-molecule inhibitors of prostate-specific membrane antigen (PSMA), and α- and β-emitting radioisotopes have gained popularity in early phase clinical trials, particularly in PSMA expressed prostate cancer [4,5,6,7,8].